Acrux Limited to present at ASX Small and Mid-Cap Conference

Acrux Limited (ASX:ACR) is set to present at the ASX Small and Mid Cap Conference in Sydney, Australia on Wednesday, 25 September 2024. CEO and Managing Director, Michael Kotsanis, will deliver the presentation at 11.27am, focusing on Acrux's specialty pharmaceutical products and growth platform.

Executive Commentary on Acrux's Growth Platform

Acrux is a specialty pharmaceutical company with a successful track record in developing and commercializing topically applied pharmaceutical products. We have leveraged our 25 years of experience to market several products worldwide, particularly in the United States. Our focus on developing a range of topical generic products has been supported by our skilled workforce, on-site laboratories, and technical, clinical, and commercial expertise. We are committed to exploring commercial partnering and product development opportunities to bring affordable products to the market.

Summary of Acrux's ASX Small and Mid-Cap Conference Presentation

Acrux Limited's presentation at the ASX Small and Mid-Cap Conference highlighted the company's focus on developing and commercializing topically applied pharmaceutical products. With a successful track record and a strong growth platform, Acrux is well-positioned to continue its development of generic topical drugs. The company has already launched products in the United States and has additional launches planned, demonstrating its commitment to growth and sustainability. Acrux's expertise, capabilities, and pipeline of products under development indicate a positive outlook for the company's future in the pharmaceutical industry.